
X
Oxford BioTherapeutics to research cell therapies for Gilead’s Kite
https://pharmaphorum.com/news/oxford-biotherapeutics-to-research-cell-therapies-for-gileads-kite/
Belldegrun and Chang’s Allogene to take over from Pfizer in R&D deal
Gilead’s focus shifts from hepatitis C to CAR-T
Cost of Novartis’ revolutionary therapy is obstacle, says CMO.
Gilead has sealed a deal to acquire cell therapy leader Kite for just under $12 billion.